Table 5.

Ongoing clinical trials of combination therapy in ASPS.

Trial number	Phase	Drug	Disease	Primary endpoint	Status completion date
NCT03880123	I	Selinexor and Ixazomib	Advanced Sarcoma (ASPS)	MTD	Withdrawn November 2020
NCT01532687	II	Gemcitabine Alone or in Combination With Pazopanib	Refractory STS (ASPS)	PFS	Completed October, 2019
NCT02636725	II	Concurrent Axitinib and Pembrolizumab	Advanced ASPS	PFS	Active, December, 2022 not recruiting
NCT03989596	II	Hypofractionated RT (10x 3.25 Gy) and Deep hyperthermia	Unresectable STS (ASPS)	Rate of grade 3	Active, December, 2022 not recruiting
NCT03277924	I/II	Sunitinib Plus Nivolumab	Advanced STS (ASPS)	PFSR at 6 months	Recruiting September, 2022
NCT04332874	II	Pembrolizumab + infusion of melphalan and dactinomycin	Advanced ASPS	PFS	Recruiting April, 2023